A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory Non-Hodgkin lymphoma

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 987-994

  Srivastava, Shivani ^a   Jones, David ^a   Wood, Lisa L ^a   Schwartz, Jennifer E ^a   Nelson, Robert P ^a   Abonour, Rafat ^a   Secrest, Angie ^a   Cox, Elizabeth ^a   Baute, Jay ^a   Sullivan, Cheryl ^a   Kane, Kathleen ^a   Robertson, Michael J ^a   Farag, Sherif S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous stem cell transplantation; Clofarabine; Non Hodgkins lymphoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG FEVER; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HAND FOOT SYNDROME; HEMORRHAGIC CYSTITIS; HERPETIC STOMATITIS; HUMAN; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG-INDUCED LIVER INJURY; ETOPOSIDE; FEMALE; FILGRASTIM; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79958758227     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.016     Document Type: Article

References (32)

1. Armitage J.O. Bone marrow transplantation. N Engl J Med 1994, 330:827-838.
2. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987, 316:1493-1498.
3. Copelan E.A., Penza S.L., Pohlman B., et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 25:1243-1248.
4. Robertson M.J., Abonour R., Hromas R., Nelson R.P., Fineberg N.S., Cornetta K. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2005, 46:1477-1487.
5. Stiff P.J., Unger J.M., Forman S.J., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003, 9:529-539.
6. Collins C., Mortimer J., Livingston R.B. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989, 63:228-232.
7. Dombernowsky P., Nissen N.I. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Eur J Cancer 1976, 12:181-188.
8. Chang T.T., Gulati S., Chou T.C., Colvin M., Clarkson B. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors. Cancer Res 1987, 47:119-122.
9. O'Dwyer P.J., Leyland-Jones B., Alonso M.T., Marsoni S., Wittes R.E. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985, 312:692-700.
10. Puig N., de la Rubia J., Remigia M.J., et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006, 47:1488-1494.
11. Hartman A.R., Williams S.F., Dillon J.J. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998, 22:439-443.
12. Miller J.S., Arthur D.C., Litz C.E., Neglia J.P., Miller W.J., Weisdorf D.J. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994, 83:3780-3786.
13. Stone R.M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994, 12:2535-2542.
14. Jeha S., Gaynon P.S., Razzouk B.I., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006, 24:1917-1923.
15. Kantarjian H., Gandhi V., Cortes J., et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
16. Kantarjian H.M., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
17. Gandhi V., Plunkett W., Bonate P.L., et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006, 12:4011-4017.
18. Nabhan C., Fried W., Galvez A., Venugopal P., Bitran J. Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL). J Clin Oncol 2008, 26:470.
19. Blum K.A., Hamadani M., Phillips G.S., et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009, 50:349-356.
20. Parker W.B., Shaddix S.C., Rose L.M., et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999, 55:515-520.
21. Xie K.C., Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996, 56:3030-3037.
22. Yamauchi T., Nowak B.J., Keating M.J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 7:3580-3589.
23. Montoto S., Lopez-Guillermo A., Altes A., et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004, 15:1484-1489.
24. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
25. Genini D., Adachi S., Chao Q., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537-3543.
26. Farag S.S., Wood L., Schwartz J.E., et al. Phase I trial of high-dose clofarabine and busulfan as a myeloablative regimen prior to allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute leukemia. Blood 2009, 114:198.
27. Cunningham C.C., Nemunaitis J., Senzer N., et al. Clofarabine adiministration weekly to adult patients with advanced solid tumors in a phase I dose-finding study. J Clin Oncol 2005, 23:647s.
28. Hijiya N., Gaynon P., Barry E., et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009, 23:2259-2264.
29. McGregor B.A., Brown A.W., Osswald M.B., Savona M.R. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009, 84:228-230.
30. Bonate P.L., Craig A., Gaynon P., et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004, 44:1309-1322.
31. Gandhi V., Kantarjian H., Faderl S., et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003, 9:6335-6342.
32. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.